Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cellegy Pharmaceuticals (CLGY) -- Ignore unavailable to you. Want to Upgrade?

To: Howard Hoffman who wrote (226)	2/17/2000 8:51:00 AM
From: Magic212	Respond to of 322

We've got a little press this morning... From Thom Calandra's column on CBS MarketWatch... cbs.marketwatch.com Biomedical melt-up: Biotechnology shares Wednesday turned in one of their best single-day performances ever. Various biotech stock indexes in the U.S. stock market rose 12 percent and more for the day -- after positive patent news for a gene sciences company. See the story. It was the little-known biotechnology stocks that had a real field day. One of them, tiny Cellegy Pharmaceuticals (CLGY: news, msgs), saw its shares rise 29 percent. The South San Francisco company is developing ointments that treat damaged and wrinkled skin. One ointment is being tested as a salve for hemorrhoid symptoms. Other products address waning sexual energy in aging men. Another tiny company, Alliance Pharmaceutical (ALLP: news, msgs), saw its shares rise 15 percent. A product the San Diego company is testing in clinical trials just might ease blood shortages, an Alliance CEO told a New York City biotech investment conference. See story for more on the conference. Bulletin-board stocks -- sometimes known as penny stocks -- fared best of all. One of them, Advanced Viral Research (ADVR: news, msgs) of Yonkers, N.Y., saw its shares rise 26 percent as 35 million shares changed hands. The stock sells for 38 cents, giving the company a market worth of $117 millio